HCW Biologics Inc.
HCWB evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for HCWB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · HCWB
HCW Biologics Inc. (HCWB) is a clinical-stage biopharmaceutical company developing immunotherapeutics for cancer and aging-related diseases, currently advancing preclinical candidates toward IND filings while managing a limited cash position.
Key risk: Cash runway risk
BioSniper Score
Based on 6 of 6 signals
Market Cap
$6.3M
Cash Runway
0.7 moLead Asset
hcw9302 (Phase 1)
Next Catalyst
Phase3_Topline · Dec 31, 2027Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 18 clinical trials · 1 catalyst for HCW Biologics Inc..
HCW Biologics Inc. (HCWB) is a clinical-stage biopharmaceutical company developing immunotherapeutics for cancer and aging-related diseases, currently advancing preclinical candidates toward IND filings while managing a limited cash position.
- Cash & equivalents of $0.7M as of 2026-06-30, with net income of -$5.2M for the six months ended June 30, 2026 [sec].
- Total revenue of $0.1M for the six months ended June 30, 2026, reflecting minimal product revenue [sec].
- Shareholders' equity of $2.8M and total debt of $6.6M as of 2026-06-30 [sec].
- Plans to file an IND for HCW11-018b in cancer in the first half of 2027 and for HCW11-040 in bronchopulmonary dysplasia in the second half of 2027 [sec_mda · as of 2026-08-14].
- The company has raised $11.5M in equity in 2025 and extinguished $7.7M of debt through restructuring and conversion [sec_mda · as of 2026-03-31].
What works
- The company has successfully raised $11.5 million in equity during 2025 and extinguished $7.7 million of debt through restructuring and conversion, improving its balance sheet [sec_mda · as of 2026-03-31].
- HCW Biologics has identified HCW11-040 as a lead second-generation immune checkpoint inhibitor with potential for treating large unmet medical needs in cancer and aging-related diseases [sec_mda · as of 2025-11-14].
- The company is advancing two product candidates toward IND filings, with HCW11-018b targeting cancer and HCW11-040 targeting bronchopulmonary dysplasia, a chronic lung disease in premature infants [sec_mda · as of 2026-08-14].
What to weigh
- As of June 30, 2026, the company had only $0.7 million in cash and equivalents, with a net loss of $5.2 million for the six-month period, indicating a very limited cash runway [sec].
- The company has a history of substantial doubt about its ability to continue as a going concern, as noted in its SEC filings [sec_mda · as of 2025-11-14].
- Total debt of $6.6 million exceeds shareholders' equity of $2.8 million as of June 30, 2026, reflecting a leveraged balance sheet [sec].
- The company is still in preclinical stages for its lead candidates, with no approved products or ongoing pivotal trials, and faces significant development risks [sec_mda · as of 2026-08-14].
From the filings
Quoted directly from source documents.
Plans to file IND for HCW11-018b in first half of 2027
“The Company intends to file an IND-application to seek authorization to evaluate HCW11-018b in a Phase 1 clinical study in patients with cancer in the first half of 2027”
SEC MD&A · August 14, 2026
Substantial doubt about going concern
“result, there was substantial doubt over whether the Company had sufficient capital to operate for the next twelve months from the issuance date of this Quarterly Report.”
SEC MD&A · November 14, 2025
Debt restructuring and equity raise in 2025
“the Company strengthened our balance sheet by extinguishing $7.7 million of debt through restructuring and conversion to equity”
SEC MD&A · March 31, 2026
Catalyst timeline
- 2027-12-31 · Phase3_Topline — Phase 3 Topline: Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles for Hospitalized Patients With Mode — Topline data from a Phase 3 trial of bone marrow mesenchymal stem cell derived extracellular vesicles for hospitalized patients; this appears to be a placeholder or misattributed catalyst and should be verified.
Risks & what to watch (4)›
Key risks
- Cash runway risk — With only $0.7M cash and a $5.2M net loss in six months, the company may need additional funding within the next year [sec].
- Going concern uncertainty — Management has previously expressed substantial doubt about the company's ability to continue as a going concern [sec_mda · as of 2025-11-14].
- Preclinical stage pipeline — All product candidates are in preclinical development; no IND has been filed yet, and clinical success is uncertain [sec_mda · as of 2026-08-14].
- High debt relative to equity — Total debt of $6.6M exceeds shareholders' equity of $2.8M, indicating financial leverage [sec].
What to watch
- IND filing for HCW11-018b in cancer, expected in the first half of 2027 [sec_mda · as of 2026-08-14].
- IND filing for HCW11-040 in bronchopulmonary dysplasia, expected in the second half of 2027 [sec_mda · as of 2026-08-14].
- Any additional equity or debt financing to extend cash runway beyond the current $0.7M [sec].
- Progress in preclinical studies and potential partnership announcements for the T-cell engager program [sec_mda · as of 2025-11-14].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run HCW Biologics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available HCW Biologics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
0.7 months
D/E 2.60 · 0% dilution
Lead: Phase 1
1 candidate
1 upcoming, next in ~488d
6 buys · 0 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
12
Total value held
$45K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 35,886 | $13K |
| citadel advisors llc | 26,083 | $9K |
| vanguard capital management llc | 24,046 | $9K |
| jane street group, llc | 14,134 | $5K |
| citigroup inc | 10,528 | $4K |
| golden state wealth management, llc | 10,000 | $4K |
| vanguard fiduciary trust co | 1,903 | $685 |
| wells fargo & company/mn | 1,000 | $360 |
| hrt financial lp | 266,393 | $95 |
| osaic holdings, inc. | 26 | $9 |
Showing top 10 of 12 institutional holders of HCW Biologics Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 9.3%
- Days to cover
- 0.3
- Shares short
- 570,862
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
HCWB short interestGovernance
Frequently asked questions
What is the AI investment thesis for HCW Biologics Inc.?
HCW Biologics Inc. (HCWB) is a clinical-stage biopharmaceutical company developing immunotherapeutics for cancer and aging-related diseases, currently advancing preclinical candidates toward IND filings while managing a limited cash position.
What is HCW Biologics Inc.'s lead drug candidate?
HCW Biologics Inc.'s most advanced tracked candidate is hcw9302 (Phase 1) for Alopecia Areata(AA).
What is HCW Biologics Inc.'s next catalyst?
HCW Biologics Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles for Hospitalized Patients With Mode" — expected December 31, 2027.
Who is the CEO of HCW Biologics Inc.?
Dr. Hing C. Wong Ph.D. is the chief executive officer of HCW Biologics Inc. (HCWB).
Where is HCW Biologics Inc. headquartered?
HCW Biologics Inc. (HCWB) is headquartered in Miramar, FL, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.